Loading
A phase 3 trial of Sunvozertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal (Jiangsu) Pharmaceutical Co., Ltd., now recruiting.
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery is a phase 3 interventional study registered as NCT07182682 by Dizal (Jiangsu) Pharmaceutical Co., Ltd., with 360 participants planned, started 2025-12-01 and due to reach its primary completion in 2029-09. Interventions recorded: sunvozertinib, Matching Placebo. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.